Belotecan (CKD-602) hydrochloride

Belotecan (CKD-602) hydrochloride (CAS No.: 213819-48-8) is a synthetic camptothecin derivative classified as a small molecule topoisomerase I inhibitor and is widely used as a research reagent in oncology focused life sciences studies, where it serves as a mechanistic probe for DNA damage associated stress responses and replication dependent cytotoxic processes in rapidly proliferating cells; functionally, this compound stabilizes the covalent topoisomerase I DNA cleavage complex, impedes religation of single strand breaks, and promotes replication fork collision events that activate canonical DNA damage signaling networks including ATM and ATR associated checkpoint cascades, thereby supporting pathway level interrogation of cell cycle arrest, apoptosis related signaling, and genomic instability phenotypes in tumor biology models; reported experimental potency across heterogeneous preclinical systems is generally described within nanomolar to micromolar concentration ranges depending on cell type, exposure duration, assay format, and resistance background, and in the absence of universally harmonized conditions, activity interpretation should be contextualized against study specific endpoints and comparator controls; in biomedical research and drug discovery workflows, Belotecan is commonly applied in cultured cancer cell panels, mechanism based combination screening, and translationally oriented animal efficacy studies to evaluate topoisomerase I pathway dependence, resistance mechanisms, and pharmacology informed structure activity hypotheses, with concentrations or doses used in experiments typically determined by defined experimental designs, model characteristics, and research objectives, and with GMP grade material generally selected when higher manufacturing and quality documentation standards are required for regulated preclinical research environments.